Known Mutations May Not Be Driving Immunotherapy Failure
New research into cancer "dark matter" reveals hidden cancer signals immune system can't find, offering a fuller picture of why immunotherapy fails for many patients.
72.93% Tumor Inhibition Seen in Dual-Drug Nanoparticle Mouse Study
Can nanotechnology reduce breast cancer drug side effects? This preclinical study found a dual-drug nanoparticle system cut tumor growth by 72.93% in mice.
One Drug at a Time May Be Why Immunotherapy Falls Short
This review explains the science behind cold tumor hot tumor immunotherapy how to switch, focusing on how nanocarrier delivery may reshape treatment precision in ongoing research.
TAM Center Reviews How Precision Cell Selection Could Sharpen MSC Therapies
Are all stem cell treatments the same? This review covers how MSC subpopulations defined by specific markers may explain inconsistent results seen across cell therapy trials.